Lung cancer: active therapeutic targeting and inhalational nanoproduct design

References

• Torre LA, Siegel RL, Jemal, A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594.
   PubMed Web of Science ®Google Scholar
• Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics. Cancer J Clin. 2012;62:220–241.
   PubMed Web of Science ®Google Scholar
• Litzky LA. Pulmonary sarcomatous tumors. Arch Pathol Lab Med. 2008;132:1104–1117.
   PubMed Web of Science ®Google Scholar
• Zorzetto M, Ferrari S, Saracino L, et al. MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications. Transl Lung Cancer Res. 2012;1:194–207.
   PubMedGoogle Scholar
• Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83:355–367.
   PubMed Web of Science ®Google Scholar
• Pikor LA, Ramnarine VR, Lam S, et al. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82:179–189.
   PubMed Web of Science ®Google Scholar
• Panagopoulos N, Leivaditis V, Koletsis E, et al. Pancoast tumors: characteristics and preoperative assessment. J Thorac Dis. 2014;6:S108–15.
   PubMed Web of Science ®Google Scholar
• Horn L, Pao W, David H, et al. Neoplasms of the lung. In: Harrison’s principles of internal medicine, 18th ed. New York, NY: McGraw-Hill Professional Publishing; 2011.
   Google Scholar
• Porth C. Respiratory tract infections, neoplasms, and childhood disorders. In: Essentials of pathophysiology: concepts of altered health states, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011. p. 554–557.
   Google Scholar
• Travis W, Brambilla E, Müller-Hermelin K, et al. WHO classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: World Health Organization, IARC Press; 2004.
   Google Scholar
• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thoracic Oncol. 2015;10:1243–1260.
   PubMed Web of Science ®Google Scholar
• Colby T, Koss M, Travis W. Tumors of the lower respiratory tract. In: Rosai J, Sobin L, editors. Atlas of tumor pathology. Washington, DC: Armed Forces Inst Patho; 1995. p. 14.
   Google Scholar
• Tomashefski JF, Connors AF, Rosenthal ES, et al. Peripheral vs central squamous cell carcinoma of the lung. A comparison of clinical features, histopathology, and survival. . Arch Pathol Lab Med. 1990;114:468–474.
   PubMed Web of Science ®Google Scholar
• de Groot P, Munden RF. Lung cancer epidemiology, risk factors, and prevention. Rad Clin North Am. 2012;50:863–876.
   PubMed Web of Science ®Google Scholar
• Aplin AE, Howe A, Alahari SK, et al. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev. 1998;50:197–263.
   PubMed Web of Science ®Google Scholar
• Katare DP, Mishra S, Kharkwal H, et al. Protein-drug conjugates: a new class of biotherapeutics. Kharkwal H, Janaswamy S, editors. UK: Cabi; 2017. p. 93–106.
   Google Scholar
• Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res. 2003;42:439–462.
   PubMed Web of Science ®Google Scholar
• Waters MJ. The growth hormone receptor. Growth Hormone IGF Res. 2016;28:6–10.
   PubMed Web of Science ®Google Scholar
• Cheng CY, Perevedentseva E, Tu JS, et al. Direct and in vitro observation of growth hormone receptor molecules in A549 human lung epithelial cells by nanodiamond labeling. Appl Phys Lett. 2007;90:163903.
   Web of Science ®Google Scholar
• Cao G, Lu H, Feng J, et al. Lung cancer risk associated with Thr495Pro polymorphism of GHR in Chinese population. Jap J Clin Oncol. 2008;38:308–316.
   PubMed Web of Science ®Google Scholar
• Cadranel J, Ruppert AM, Beau-Faller M, et al. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Crit Rev Oncol/Hematol. 2013;88:477–493.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Kawasaki N, Taguchi M, et al. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax. 2006;61:140–145.
   PubMed Web of Science ®Google Scholar
• Stuttfeld E, Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life. 2009;61:915–922.
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114:853–865.
   PubMed Web of Science ®Google Scholar
• Goel HL, Mercurio AM. VEGF targets the tumour cell. Cancer. 2013;13:871–882.
   PubMed Web of Science ®Google Scholar
• Danish Q, Mokhdomi TA, Bukhari S, et al. The ensemble of genetic factors and angiogenic signals via VEGF receptors in lung cancer progression. Cancer Biomarkers Sect A Dis Markers. 2015;15:619–633.
   PubMed Web of Science ®Google Scholar
• Carrillo de Santa Pau E, Arias FC, Caso Peláez E, et al. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer. 2009;115:1701–1712.
   PubMed Web of Science ®Google Scholar
• Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol. 1999;188:369–377.
   PubMed Web of Science ®Google Scholar
• Seto T, Higashiyama M, Funai H, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer. 2006;53:91–96.
   PubMed Web of Science ®Google Scholar
• Pajares MJ, Agorreta J, Larrayoz M, et al. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol. 2012;30:1129–1136.
   PubMed Web of Science ®Google Scholar
• Li Q, Dong X, Gu W, et al. Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer. Chin Med J. 2003;116:727–730.
   PubMed Web of Science ®Google Scholar
• Kojima H, Shijubo N, Yamada G, et al. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer. 2005;104:1668–1677.
   PubMed Web of Science ®Google Scholar
• Su JL, Yang PC, Shih JY, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell. 2006;9:209–223.
   PubMed Web of Science ®Google Scholar
• Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta Mol Cell Res. 2012;1823:850–860.
   PubMed Web of Science ®Google Scholar
• Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 1993;60:1–41.
   PubMed Web of Science ®Google Scholar
• Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PloS One. 2011;6:e20351.
   PubMed Web of Science ®Google Scholar
• Templeton AK, Miyamoto S, Babu A, et al. Cancer stem cells: progress and challenges in lung cancer. Stem Cell Investig. 2014 Apr;1:9.
   PubMedGoogle Scholar
• Penno MB, August JT, Baylin SB, et al. Expression of CD44 in human lung tumors. Cancer Res. 1994;54:1381–1387.
   PubMed Web of Science ®Google Scholar
• Chinni SR, Falchetto K, Gercel-Taylor N, et al. Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients. Clin Cancer Res. 1997;3:1557–1564.
   PubMed Web of Science ®Google Scholar
• Wang FL, Wei LX. Expression of CD44 variant exon 6 in lung cancers. Acta Acad Med Sin. 2001;23:401–402.
   Google Scholar
• Zhao S, He JL, Qiu ZX, et al. Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: a meta-analysis. Asian Pacific J Cancer Prevent. 2014;15:6761–6766.
   PubMedGoogle Scholar
• Hynes RO. Integrins: bidirectional allosteric signaling machines. Cell. 2002;110:673–687.
   PubMed Web of Science ®Google Scholar
• Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 2010;339:269–280.
   PubMed Web of Science ®Google Scholar
• Bartolazzi A, Cerboni C, Flamini G, et al. Expression of alpha 3 beta 1 integrin receptor and its ligands in human lung tumors. Int J Cancer. 1995;64:248–252.
   PubMed Web of Science ®Google Scholar
• Barr LF, Campbell SE, Bochner BS, et al. Association of the decreased expression of α 3 β 1 integrin with the altered cell : environmental interactions and enhanced soft agar cloning ability of c-myc-overexpressing small cell lung cancer cells. Cancer Res. 1998;58:5537–5545.
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nature Rev Immunol. 2011;11:597–606.
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–127.
   PubMed Web of Science ®Google Scholar
• Wu B, Chien EYT, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Sci. 2010;330:1066–1071.
   PubMed Web of Science ®Google Scholar
• Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012;13:287–297.
   PubMed Web of Science ®Google Scholar
• Wald O, Izhar U, Amir G, et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol. 2006;177:6983–6990.
   PubMed Web of Science ®Google Scholar
• Nelson RM, Venot A, Bevilacqua MP, et al. Carbohydrate-protein interactions in vascular biology. Annu Rev Cell Dev Biol. 1995;11:601–631.
   PubMed Web of Science ®Google Scholar
• Varki A. Selectin ligands. Proc Nat Acad Sci USA. 1994;91:7390–7397.
   PubMed Web of Science ®Google Scholar
• Guney N, Soydinc HO, Derin D, et al. Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer. Med Oncol. 2008;25:194–200.
   PubMed Web of Science ®Google Scholar
• Hiratsuka S, Goel S, Kamoun WS, et al. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proc Nat Acad Sci USA. 2011;108:3725–3730.
   PubMed Web of Science ®Google Scholar
• Martín-Satué M, Marrugat R, Cancelas JA, et al. Enhanced expression of α (1, 3)-fucosyltransferase genes correlates with E-selectin-mediated adhesion and metastatic potential of human lung adenocarcinoma cells. Cancer Res. 1998;58:1544–1550.
   PubMed Web of Science ®Google Scholar
• Gong L, Mi HJ, Zhu H, et al. P-selectin-mediated platelet activation promotes adhesion of non-small cell lung carcinoma cells on vascular endothelial cells under flow. Mol Med Rep. 2012;5:935–942.
   PubMed Web of Science ®Google Scholar
• Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol. 1997;139:1337–1348.
   PubMed Web of Science ®Google Scholar
• Balzar M, Winter MJ, de Boer CJ, et al. The biology of the 17-1A antigen (Ep-CAM). J Mol Med. 1999;77:699–712.
   PubMed Web of Science ®Google Scholar
• Went P, Vasei M, Bubendorf L, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006;94:128–135.
   PubMed Web of Science ®Google Scholar
• Piyathilake CJ, Frost AR, Weiss H, et al. The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. Human Patho. 2000;31:482–487.
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim HS, Cui ZY, et al. Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. Anticancer Res. 2009;29:1817–1822.
   PubMed Web of Science ®Google Scholar
• Varnum BC, Young C, Elliott G, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature. 1995;373:623–626.
   PubMed Web of Science ®Google Scholar
• Costa M, Bellosta P, Basilico C. Cleavage and release of a soluble form of the receptor tyrosine kinase ARK in vitro and in vivo. J Cell Physiol. 1996;168:737–744.
   PubMed Web of Science ®Google Scholar
• O’Bryan JP, Fridell YW, Koski R, et al. The transforming receptor tyrosine kinase Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem. 1995;270:551–557.
   PubMed Web of Science ®Google Scholar
• Paccez JD, Vogelsang M, Parker MI, et al. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int J Cancer. 2014;134:1024–1033.
   PubMed Web of Science ®Google Scholar
• Shieh YS, Lai CY, Kao YR, et al. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia. 2005;7:1058–1064.
   PubMed Web of Science ®Google Scholar
• Wimmel A, Glitz D, Kraus A, et al. Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer. 2001;37:2264–2274.
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodríguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta Gen Sub. 2012;1820:291–317.
   PubMed Web of Science ®Google Scholar
• Pun SH, Tack F, Bellocq NC, et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther. 2004;3:641–650.
   PubMed Web of Science ®Google Scholar
• Dowlati A, Loo M, Bury T, et al. Soluble and cell-associated transferrin receptor in lung cancer. Br J Cancer. 1997;75:1802–1806.
   PubMed Web of Science ®Google Scholar
• Whitney JF, Clark JM, Griffin TW, et al. Transferrin receptor expression in nonsmall cell lung cancer. Cancer. 1995;76:20–25.
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhang H, Lin Y, et al. Mechanisms of gambogic acid-induced apoptosis in non-small cell lung cancer cells in relation to transferrin receptors. J Chemother. 2009;21:666–672.
   PubMed Web of Science ®Google Scholar
• Kukulj S, Jaganjac M, Boranic M, et al. Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer. Med Oncol. 2010;27:268–277.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–682.
   PubMed Web of Science ®Google Scholar
• Cassatella MA. On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils. J Leukocyte Biol. 2006;79:1140–1149.
   PubMed Web of Science ®Google Scholar
• Daniels RA, Turley H, Kimberley FC, et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. 2005;15:430–438.
   PubMed Web of Science ®Google Scholar
• Spierings DCJ, de Vries EGE, Timens W, et al. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res. 2003;9:3397–3405.
   PubMed Web of Science ®Google Scholar
• Matherly LH, Goldman ID. Membrane transport of folates. Vitamins and hormones. 2003;66:403–456.
   Google Scholar
• Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004;56:1067–1084.
   PubMed Web of Science ®Google Scholar
• Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Analy Biochem. 2005;338:284–293.
   PubMed Web of Science ®Google Scholar
• Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 1994;73:2432–2443.
   PubMed Web of Science ®Google Scholar
• Cagle PT, Zhai QJ, Murphy L, et al. Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents. Arch Patho Lab Med. 2013;137:241–244.
   PubMed Web of Science ®Google Scholar
• Nunez MI, Behrens C, Woods DM, et al. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR mutation J. Thoracic Oncol. 2012;7:833–840.
   PubMed Web of Science ®Google Scholar
• O’Shannessy DJ, Yu G, Smale R, et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget. 2012;3:414–425.
   PubMed Web of Science ®Google Scholar
• Shi H, Guo J, Li C, et al. A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Dev Ther. 2015;9:4989–4996.
   PubMed Web of Science ®Google Scholar
• Jordinson M, Calam J, Pignatelli M. Lectins: from basic science to clinical application in cancer prevention. Exp Opin Investigat Drugs. 1998;7:1389–1403.
   PubMedGoogle Scholar
• Thöm I, Schult-Kronefeld O, Burkholder I, et al. Lectin histochemistry of metastatic adenocarcinomas of the lung. Lung Cancer. 2007;56:391–397.
   PubMed Web of Science ®Google Scholar
• Donington JS, Pass HI. Surgical approach to locally advanced non-small cell lung cancer. Cancer J. 2013;19:217–221.
   PubMed Web of Science ®Google Scholar
• Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transi Med. 2013;5:173sr2.
   PubMed Web of Science ®Google Scholar
• Yu E, Lewis C, Luisa Trejos A, et al. Lung cancer brachytherapy: robotics-assisted minimally invasive approach. Curr Resp Med Rev. 2011;7:340–353.
   Google Scholar
• Kalemkerian GP. Advances in pharmacotherapy of small cell lung cancer. Exp Opin Pharmacother. 2014;15:2385–2396.
   PubMed Web of Science ®Google Scholar
• Clegg A, Scott DA, Hewitson P, et al. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax. 2002;57:20–28.
   PubMed Web of Science ®Google Scholar
• Waqar SN, Subramanian J, Morgensztern D, et al. Chemotherapy of lung cancer. In: Perry’s the chemotherapy source book. 5th ed. Walters Kluwer: Lippincott Williams and Wilkins; 2012. 385–400.
   Google Scholar
• Stevens EA, Rodriguez CP. Genomic medicine and targeted therapy for solid tumors. J Surg Oncol. 2015;111:38–42.
   PubMed Web of Science ®Google Scholar
• Smith RE. Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. J Nat Compr Cancer Network. 2006;4:649–658.
   PubMedGoogle Scholar
• Hughes GA. Nanostructure-mediated drug delivery. Nanomed Nanotechnol Biol Med. 2005;1:22–30.
   PubMed Web of Science ®Google Scholar
• Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retinal Eye Res. 2010;29:596–609.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. Am Chem Soc Pub. 2009;3:16–20.
   Google Scholar
• Lee SH, Heng D, Ng WK, et al. Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy. Int J Pharm. 2011;403:192–200.
   PubMed Web of Science ®Google Scholar
• Plapied L, Duhem N, Des Rieux A, et al. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Coll Interf Sci. 2011;16:228–237.
   Web of Science ®Google Scholar
• Betancourt T, Doiron A, Homan KA, et al. Controlled release and nanotechnology. In: de Villiers MM, Aramwit P, Kwon GS, editors. Nanotechnology in drug delivery. New York: Springer ; 2009. p. 283–312.
   Google Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25:999–1022.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Saraf S, Asthana A, et al. Ligand based dendritic systems for tumor targeting. Int J Pharm. 2008;350:3–13.
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615–1626.
   PubMed Web of Science ®Google Scholar
• Toporkiewicz M, Meissner J, Matusewicz L, et al. Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes and challenges. Int. J. Nanomed.. 2015;10:1399–1414.
   PubMed Web of Science ®Google Scholar
• Abdelaziz HM, Gaber M, Abd-Elwakil MM, et al. Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 2018;269:374–392.
   PubMed Web of Science ®Google Scholar
• Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012;2:3–44.
   PubMed Web of Science ®Google Scholar
• Ge Y, Zhang Y, He S, et al. Fluorescence modified chitosan-coated magnetic nanoparticles for high-efficient cellular imaging. Nanoscale Res Lett. 2009;4:287–295.
   PubMed Web of Science ®Google Scholar
• Lee H, Yu MK, Park S, et al. Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. J Am Chem Soc. 2007;129:12739–12745.
   PubMed Web of Science ®Google Scholar
• Hwang DW, Ko HY, Lee JH, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nuc Med. 2010;51:98–105.
   PubMed Web of Science ®Google Scholar
• Brunel FM, Lewis JD, Destito G, et al. Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting. Nano Lett. 2010;10:1093–1097.
   PubMed Web of Science ®Google Scholar
• Aryal S, Hu CMJ, Zhang L. Polymer–cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano. 2010;4:251–258.
   PubMed Web of Science ®Google Scholar
• Mannich C, Krösche W. Ueber ein Kondensationsprodukt aus Formaldehyd. Ammoniak und Antipyrin. Arch Pharm. 1912;250:647–667.
   Google Scholar
• Xie J, Chen K, Lee HY, et al. Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J Am Chem Soc. 2008;130:7542–7543.
   PubMed Web of Science ®Google Scholar
• Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem. 2001;40:2004–2021.
   Google Scholar
• von Maltzahn G, Ren Y, Park JH, et al. In vivo tumor cell targeting with “click” nanoparticles. Bioconj Chem. 2008;19:1570–1578.
   PubMed Web of Science ®Google Scholar
• Santra S, Kaittanis C, Grimm J, et al. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small. 2009;5:1862–1868.
   PubMed Web of Science ®Google Scholar
• Hein CD, Liu XM, Wang D. Click chemistry, a powerful tool for pharmaceutical sciences. Pharm Res. 2008;25:2216–2230.
   PubMed Web of Science ®Google Scholar
• Devaraj NK, Upadhyay R, Haun JB, et al. Fast and sensitive pretargeted labeling of cancer cells through a tetrazine/trans-cyclooctene cycloaddition. Angew Chem. 2009;48:7013–7016.
   Google Scholar
• Haun JB, Devaraj NK, Hilderbrand SA, et al. Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection. Nature Nanotechnol. 2010;5:660–665.
   PubMed Web of Science ®Google Scholar
• Lu RM, Chang YL, Chen MS, et al. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomat. 2011;32:3265–3274.
   PubMed Web of Science ®Google Scholar
• Mitchell GP, Mirkin CA, Letsinger RL. Programmed assembly of DNA functionalized quantum dots. J Am Chem Soc. 1999;121:8122–8123.
   Web of Science ®Google Scholar
• Pathak S, Choi SK, Arnheim N, et al. Hydroxylated quantum dots as luminescent probes for in situ hybridization. J Am Chem Soc. 2001;123:4103–4104.
   PubMed Web of Science ®Google Scholar
• Willard DM, Carillo LL, Jung J, et al. CdSe-ZnS quantum dots as resonance energy transfer donors in a model protein-protein binding assay. Nano Lett. 2001;1:469–474.
   Web of Science ®Google Scholar
• Lu W, Zhang G, Zhang R, et al. Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res. 2010;70:3177–3188.
   PubMed Web of Science ®Google Scholar
• Dixit V, Van Den Bossche J, Sherman DM, et al. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconj Chem. 2006;17:603–609.
   PubMed Web of Science ®Google Scholar
• Heo DN, Yang DH, Moon HJ, et al. Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy. Biomat. 2012;33:856–866.
   PubMed Web of Science ®Google Scholar
• Reddy GR, Bhojani MS, McConville P, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res. 2006;12:6677–6686.
   PubMed Web of Science ®Google Scholar
• Mok H, Veiseh O, Fang C, et al. pH-Sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells. Mol Pharm. 2010;7:1930–1939.
   PubMed Web of Science ®Google Scholar
• Yu MK, Park J, Jeong YY, et al. Integrin-targeting thermally cross-linked superparamagnetic iron oxide nanoparticles for combined cancer imaging and drug delivery. Nanotechnol. 2010;21:415102.
   PubMed Web of Science ®Google Scholar
• Veiseh O, Sun C, Fang C, et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 2009;69:6200–6207.
   PubMed Web of Science ®Google Scholar
• Wu P, He X, Wang K, et al. A novel methotrexate delivery system based on chitosan-methotrexate covalently conjugated nanoparticles. J Biomed Nanotechnol. 2009;5:557–564.
   PubMed Web of Science ®Google Scholar
• Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res. 1999;5:83–94.
   PubMed Web of Science ®Google Scholar
• Zhang XQ, Xu X, Lam R, et al. Strategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA-nanoparticle conjugates. ACS Nano. 2011;5:6962–6970.
   PubMed Web of Science ®Google Scholar
• Liu T, Li X, Qian Y, et al. Multifunctional pH-disintegrable micellar nanoparticles of asymmetrically functionalized β-cyclodextrin-based star copolymer covalently conjugated with doxorubicin and DOTA-Gd moieties. Biomat. 2012;33:2521–2531.
   PubMed Web of Science ®Google Scholar
• Doane T, Burda C. Nanoparticle mediated non-covalent drug delivery. Adv Drug Deliv Rev. 2013;65:607–621.
   PubMed Web of Science ®Google Scholar
• Green NM. Avidin and streptavidin. Methods Enzymol. 1990;184:51–67.
   PubMed Web of Science ®Google Scholar
• Fehring V, Schaeper U, Ahrens K, et al. Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC. Mol Ther. 2014;22:811–820.
   PubMed Web of Science ®Google Scholar
• Won YY, Sharma R, Konieczny SF. Missing pieces in understanding the intracellular trafficking of polycation/DNA complexes. J Control Release. 2009;139:88–93.
   PubMed Web of Science ®Google Scholar
• Essex S, Navarro G, Sabhachandani P. Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors. Gene Ther. 2015;22:257–266.
   PubMed Web of Science ®Google Scholar
• Jain TK, Morales MA, Sahoo SK, et al. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm. 2005;2:194–205.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lu J, Jin Y, et al. Folate-conjugated beta-cyclodextrin-based polymeric micelles with enhanced doxorubicin antitumor efficacy. Coll Surf B Biointerf. 2014;122:260–269.
   PubMed Web of Science ®Google Scholar
• Artemov D, Mori N, Okollie B, et al. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med. 2003;49:403–408.
   PubMed Web of Science ®Google Scholar
• Varshney M, Yang L, Su XL, et al. Magnetic nanoparticle-antibody conjugates for the separation of Escherichia coli O157: h7in ground beef. J Food Prot. 2005;68:1804–1811.
   PubMed Web of Science ®Google Scholar
• Zhou J, Rossi JJ. Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. Mol Ther Nucleic Acids. 2014;3:e169.
   PubMedGoogle Scholar
• Hicke BJ, Stephens AW, Gould T, et al. Tumor targeting by an aptamer. J Nuc Med. 2006;47:668–678.
   PubMed Web of Science ®Google Scholar
• Frederick CA, Williams LD, Ughetto G, et al. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochem. 1990;29:2538–2549.
   PubMed Web of Science ®Google Scholar
• Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano. 2010;4:3689–3696.
   PubMed Web of Science ®Google Scholar
• Yu MK, Kim D, Lee IH, et al. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small. 2011;7:2241–2249.
   PubMed Web of Science ®Google Scholar
• Torchilin V. Antibody-modified liposomes for cancer chemotherapy. Exp Opin Drug Deliv. 2008;5:1003–1025.
   PubMed Web of Science ®Google Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nature Rev Cancer. 2002;2:750–763.
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301–311.
   PubMed Web of Science ®Google Scholar
• Humblet Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Exp Opin Pharmacother. 2004;5:1621–1633.
   PubMed Web of Science ®Google Scholar
• Karra N, Nassar T, Ripin AN, et al. Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model. Small. 2013;9:4221–4236.
   PubMed Web of Science ®Google Scholar
• Danesi R, Pasqualetti G, Giovannetti E, et al. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv Drug Deliv Rev. 2009;61:408–417.
   PubMed Web of Science ®Google Scholar
• Wang XB, Zhou HY. Molecularly targeted gemcitabine-loaded nanoparticulate system towards the treatment of EGFR overexpressing lung cancer. Biomed Pharmacother. 2015;70:123–128.
   PubMed Web of Science ®Google Scholar
• Maya S, Sarmento B, Lakshmanan V, et al. Chitosan cross-linked docetaxel loaded EGF receptor targeted nanoparticles for lung cancer cells. Int J Biol Macromol. 2014;69:532–541.
   PubMed Web of Science ®Google Scholar
• Lee YK, Lee TS, Song IH, et al. Inhibition of pulmonary cancer progression by epidermal growth factor receptor-targeted transfection with Bcl-2 and survivin siRNAs. Cancer Gene Ther. 2015;22:335–343.
   PubMed Web of Science ®Google Scholar
• Jo S, Noh S, Jin Z, et al. Simple and efficient capture of EGFR-expressing tumor cells using magnetic nanoparticles. Sens Actuators B Chem. 2014;201:144–152.
   Web of Science ®Google Scholar
• Ahmad I, Longenecker M, Samuel J, et al. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 1993;53:1484–1488.
   PubMed Web of Science ®Google Scholar
• Xu H, Ma H, Yang P, et al. Targeted polymer-drug conjugates: current progress and future perspective. Coll Surf B Biointerf. 2015;136:729–734.
   PubMed Web of Science ®Google Scholar
• McGuire M, Li S, Brown K. Biopanning of phage displayed peptide libraries for the isolation of cell-specific ligands. In: Rasooly A, Herold KE, editors. Biosensors and biodetection SE-18. Totowa, NJ: Humana Press 504; 2009. p. 291–321.
   Google Scholar
• Chang CC, Chen PH, Chu HL, et al. Laser induced popcornlike conformational transition of nanodiamond as a nanoknife. Appl Phys Lett. 2008;93:33905.
   Web of Science ®Google Scholar
• Cheng L, Huang FZ, Cheng LF, et al. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation. Int J Nanomed. 2014;9:921–935.
   PubMed Web of Science ®Google Scholar
• Togami K, Miyao A, Miyakoshi K, et al. Efficient delivery to human lung fibroblasts (WI-38) of pirfenidone incorporated into liposomes modified with truncated basic fibroblast growth factor and its inhibitory effect on collagen synthesis in idiopathic pulmonary fibrosis. Biol Pharm Bull. 2015;38:270–276.
   PubMed Web of Science ®Google Scholar
• Wu Y, Lu CT, Li WF, et al. Preparation and antitumor activity of bFGF-mediated active targeting doxorubicin microbubbles. Drug Dev Ind Pharm. 2013;39:1712–1719.
   PubMed Web of Science ®Google Scholar
• Chang DK, Lin CT, Wu CH, et al. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PloS One. 2009;4:e4171.
   PubMed Web of Science ®Google Scholar
• El-Mousawi M, Tchistiakova L, Yurchenko L, et al. A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library. The J Biol Chem. 2003;278:46681–46691.
   PubMed Web of Science ®Google Scholar
• Chang DK, Li PC, Lu RM, et al. Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models. PloS One. 2013;8:e83239.
   PubMed Web of Science ®Google Scholar
• Hai-Tao Z, Hui-Cheng L, Zheng-Wu L, et al. A tumor-penetrating peptide modification enhances the antitumor activity of endostatin in vivo. Anticancer Drugs. 2011;22:409–415.
   PubMed Web of Science ®Google Scholar
• Teesalu T, Sugahara KN, Kotamraju VR, et al. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci. 2009;106:16157–16162.
   PubMed Web of Science ®Google Scholar
• Lao X, Li B, Liu M, et al. Increased antitumor activity of tumor-specific peptide modified thymopentin. Biochimie. 2014;107:277–285.
   PubMed Web of Science ®Google Scholar
• Shen J, Meng Q, Sui H, et al. iRGD conjugated TPGS mediates codelivery of paclitaxel and survivin shRNA for the reversal of lung cancer resistance. Mol Pharm. 2014;11:2579–2591.
   PubMed Web of Science ®Google Scholar
• Dewan MZ, Ahmed S, Iwasaki Y, et al. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 2006;60:273–276.
   PubMed Web of Science ®Google Scholar
• Tang CH, Tan TW, Fu WM, et al. Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogen. 2008;29:35–43.
   PubMed Web of Science ®Google Scholar
• Tsutsumi H, Tanaka T, Ohashi N, et al. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolym. 2007;88:279–289.
   PubMed Web of Science ®Google Scholar
• Wang RT, Zhi XY, Yao SY, et al. LFC131 peptide-conjugated polymeric nanoparticles for the effective delivery of docetaxel in CXCR4 overexpressed lung cancer cells. Coll Surf B Biointerf. 2015;133:43–50.
   PubMed Web of Science ®Google Scholar
• Chittasupho C, Lirdprapamongkol K, Kewsuwan P, et al. Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles. Eur J Pharm Biopharm. 2014;88:529–538.
   PubMed Web of Science ®Google Scholar
• Liang Z, Yang N, Jiang Y, et al. Targeting docetaxel-PLA nanoparticles simultaneously inhibit tumor growth and liver metastases of small cell lung cancer. Int J Pharm. 2015;494:337–345.
   PubMed Web of Science ®Google Scholar
• Gao H, Zhang Q, Yang Y, et al. Tumor homing cell penetrating peptide decorated nanoparticles used for enhancing tumor targeting delivery and therapy. Int J Pharm. 2015;478:240–250.
   PubMedGoogle Scholar
• Pooja D, Kulhari H, Tunki L, et al. Nanomedicines for targeted delivery of etoposide to non-small cell lung cancer using transferrin functionalized nanoparticles. RSC Adv. 2015;5:49122–49131.
   Web of Science ®Google Scholar
• Kannagi R, Izawa M, Koike T, et al. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci. 2004;95:377–384.
   PubMed Web of Science ®Google Scholar
• Shamay Y, Raviv L, Golan M, et al. Inhibition of primary and metastatic tumors in mice by E-selectin-targeted polymer–drug conjugates. J Control Release. 2015;217:102–112.
   PubMed Web of Science ®Google Scholar
• Fukuda MN, Ohyama C, Lowitz K, et al. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res. 2000;60:450–456.
   PubMed Web of Science ®Google Scholar
• Raza A, Franklin MJ, Dudek AZ. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol. 2010;85:593–598.
   PubMed Web of Science ®Google Scholar
• Guan Y, Luan X, Xu J, et al. Selective eradication of tumor vascular pericytes by peptide- conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis. Biomat. 2014;35:3060–3070.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188:759–768.
   PubMed Web of Science ®Google Scholar
• Simberg D, Duza T, Park JH, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Nat Acad Sci. 2007;104:932–936.
   PubMed Web of Science ®Google Scholar
• Kruse AM, Meenach SA, Anderson KW, et al. Synthesis and characterization of CREKA-conjugated iron oxide nanoparticles for hyperthermia applications. Acta Biomater. 2014;10:2622–2629.
   PubMed Web of Science ®Google Scholar
• Fang X, Tan W. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res. 2010;43:48–57.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Exp Opin Drug Deliv. 2006;3:311–324.
   PubMed Web of Science ®Google Scholar
• Alibolandi M, Ramezani M, Abnous K, et al. In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer. J Control Release. 2015;209:88–100.
   PubMed Web of Science ®Google Scholar
• Askarian S, Abnous K, Taghavi S, et al. Cellular delivery of shRNA using aptamer-conjugated PLL-alkyl-PEI nanoparticles. Coll Surf B Biointerf. 2015;136:355–364.
   PubMed Web of Science ®Google Scholar
• Esposito CL, Cerchia L, Catuogno S, et al. Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Mol Ther. 2014;22:1151–1163.
   PubMed Web of Science ®Google Scholar
• Yu L, Hu Y, Duan J, et al. A novel approach of targeted immunotherapy against adenocarcinoma cells with nanoparticles modified by CD16 and MUC1 aptamers. J Nanomat. 2015;2015:316968.
   Google Scholar
• Kaur J, Tikoo K. Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation. Oncogene. 2015;34:5216–5228.
   PubMed Web of Science ®Google Scholar
• Ohannesian DW, Lotan D, Thomas P, et al. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res. 1995;55:2191–2199.
   PubMed Web of Science ®Google Scholar
• Elgavish S, Shaanan B. Lectin-carbohydrate interactions: different folds, common recognition principles. Trends Biochem Sci. 1997;22:462–467.
   PubMed Web of Science ®Google Scholar
• Fakhari A, Berkland C. Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment. Acta Biomater. 2013;9:7081–7092.
   PubMed Web of Science ®Google Scholar
• Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004;95:930–935.
   PubMed Web of Science ®Google Scholar
• Ruhela D, Kivimäe S, Szoka FC. Chemoenzymatic synthesis of oligohyaluronan-lipid conjugates. Bioconj Chem. 2014;25:718–723.
   PubMed Web of Science ®Google Scholar
• Lin CM, Kao WC, Yeh CA, et al. Hyaluronic acid-fabricated nanogold delivery of the inhibitor of apoptosis protein-2 siRNAs inhibits benzo[a]pyrene-induced oncogenic properties of lung cancer A549 cells. Nanotechnol. 2015;26:105101.
   PubMed Web of Science ®Google Scholar
• Quan YH, Kim B, Park J, et al. Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44. Expt Lung Res. 2014;40:475–484.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Huo ZJ, Liu K, et al. Ligand-conjugated pH-sensitive polymeric micelles for the targeted delivery of gefitinib in lung cancers. RSC Adv. 2015;5:73184–73193.
   Web of Science ®Google Scholar
• Drabovich AP, Berezovski MV, Musheev MU, et al. Selection of smart small-molecule ligands: the proof of principle. Analy Chem. 2009;81:490–494.
   PubMed Web of Science ®Google Scholar
• Muthukumar T, Chamundeeswari M, Prabhavathi S, et al. Carbon nanoparticle from a natural source fabricated for folate receptor targeting, imaging and drug delivery application in A549 lung cancer cells. Eur J Pharm Biopharm. 2014;88:730–736.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Hu Y, Yang J, et al. Facile synthesis of folic acid-modified iron oxide nanoparticles for targeted MR imaging for pulmonary tumor xenografts. Mol Imag Biol. 2016;18:569–578.
   PubMed Web of Science ®Google Scholar
• Wang S, Luo J, Lantrip DA, et al. Design and synthesis of [111In]DPTA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjugate Chem. 1997;8:673–679.
   PubMed Web of Science ®Google Scholar
• Rosière R, Van Woensel M, Gelbcke M, et al. New folate-grafted chitosan derivative to improve delivery of paclitaxel-loaded solid lipid nanoparticles for lung tumor therapy by inhalation. Mol Pharm. 2018;15:899–910.
   PubMed Web of Science ®Google Scholar
• Rosière R, Van Woensel M, Mathieu V, et al. Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy. Int J Pharm. 2016;501:148–159.
   PubMedGoogle Scholar
• Hu L, Pang S, Hu Q, et al. Enhanced antitumor efficacy of folate targeted nanoparticles co-loaded with docetaxel and curcumin. Biomed Pharmacother. 2015;75:26–32.
   PubMed Web of Science ®Google Scholar
• Sung J, Padilla D, Garcia-Contreras L, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res. 2009;26:1847–1855.
   PubMed Web of Science ®Google Scholar
• Cheow WS, Chang MW, Hadinoto K. Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile. Pharm Res. 2010;27:1597–1609.
   PubMed Web of Science ®Google Scholar
• Suk JS, Lai SK, Boylan NJ, et al. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomed. 2011;6:365–375.
   PubMed Web of Science ®Google Scholar
• Azarmi S, Roa WH, Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60:863–875.
   PubMed Web of Science ®Google Scholar
• Roa WH, Azarmi S, Al-Hallak MHDK, et al. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release. 2011;150:49–55.
   PubMed Web of Science ®Google Scholar
• Mangal S, Gao W, Li T, et al. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin. 2017;38:782–797.
   PubMed Web of Science ®Google Scholar
• Komenek S, Luesakul U, Ekgasit S, et al. Nanogold-gallate chitosan-targeted pulmonary delivery for treatment of lung cancer. AAPS PharmSciTech. 2017;18:1104–1115.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Osama K, Jamal QMS, et al. Advances and implications in nanotechnology for lung cancer management. Curr Drug Metab. 2017;18:30–38.
   PubMed Web of Science ®Google Scholar
• Traini D, Young PM. Formulation of inhalation medicines. In: Colombo P, Traini D, Buttini F, editors. Inhalation drug delivery: techniques and products. West Sussex: John Wiley & Sons, Ltd; 2012. p. 31–45.
   Google Scholar
• Carvalho TC, Peters JI, Williams RO. Influence of particle size on regional lung deposition–what evidence is there? Int J Pharm. 2011;406:1–10.
   PubMed Web of Science ®Google Scholar
• Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392:1–19.
   PubMed Web of Science ®Google Scholar
• Tsapis N, Bennett D, Jackson B, et al. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Nat Acad Sci. 2002;99:12001–12005.
   PubMed Web of Science ®Google Scholar
• Noraizaan AN, Wong TW. Physicochemical effects of lactose microcarrier on inhalation performance of rifampicin in polymeric nanoparticles. Powder Technol. 2017;310:272–281.
   Web of Science ®Google Scholar
• Wong TW, John P. Advances in spray drying technology for nanoparticle formation. In: Aliofkhazraei M, editor. Handbook of nanoparticles. 1 ed. Switzerland: Springer International Publishing; 2016. p. 329–346.
   Google Scholar
• Hadinoto K, Cheow WS. Hollow spherical nanoparticulate aggregates as potential ultrasound contrast agent: shell thickness characterization. Drug Dev Ind Pharm. 2009;35:1167–1179.
   PubMed Web of Science ®Google Scholar
• Kho K, Hadinoto K. Aqueous re-dispersibility characterization of spray-dried hollow spherical silica nano-aggregates. Powder Technol. 2010;198:354–363.
   Web of Science ®Google Scholar
• Anton N, Jakhmola A, Vandamme TF. Trojan microparticles for drug delivery. Pharma. 2012;4:1–25.
   Google Scholar
• Kawakami K, Sumitani C, Yoshihashi Y, et al. Investigation of the dynamic process during spray-drying to improve aerodynamic performance of inhalation particles. Int J Pharm. 2010;390:250–259.
   PubMed Web of Science ®Google Scholar
• Cheow WS, Li S, Hadinoto K. Spray drying formulation of hollow spherical aggregates of silica nanoparticles by experimental design. Chem Eng Res Des. 2010;88:673–685.
   Web of Science ®Google Scholar
• Hadinoto K, Phanapavudhikul P, Kewu Z, et al. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids. Int J Pharm. 2007;333:187–198.
   PubMed Web of Science ®Google Scholar
• Kho K, Hadinoto K. Effects of excipient formulation on the morphology and aqueous re-dispersibility of dry-powder silica nano-aggregates. Coll Surf A Physicochem Eng Aspects. 2010;359:71–81.
   Web of Science ®Google Scholar
• Tomoda K, Ohkoshi T, Nakajima T, et al. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Coll Surf B Biointerf. 2008;64:70–76.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Hoshina W, Kurashima H, et al. Engineering of poly(DL-lactic-co-glycolic acid) nanocomposite particles for dry powder inhalation dosage forms of insulin with the spray-fluidized bed granulating system. Adv Powder Technol. 2007;18:215–228.
   Web of Science ®Google Scholar
• Lebhardt T, Roesler S, Uusitalo HP, et al. Surfactant-free redispersible nanoparticles in fast-dissolving composite microcarriers for dry-powder inhalation. Eur J Pharm Biopharm. 2011;78:90–96.
   PubMed Web of Science ®Google Scholar
• Ali ME, Lamprecht A. Spray freeze drying for dry powder inhalation of nanoparticles. Eur J Pharm Biopharm. 2014;87:510–517.
   PubMed Web of Science ®Google Scholar
• Kunda NK, Alfagih IM, Dennison SR, et al. Bovine serum albumin adsorbed PGA-CO-PDL nanocarriers for vaccine delivery via dry powder inhalation. Pharm Res. 2015;32:1341–1353.
   PubMed Web of Science ®Google Scholar
• Stocke NA, Meenach SA, Arnold SM, et al. Formulation and characterization of inhalable magnetic nanocomposite microparticles (MnMs) for targeted pulmonary delivery via spray drying. Int J Pharm. 2015;479:320–328.
   PubMed Web of Science ®Google Scholar
• Iskandar F, Gradon L, Okuyama K. Control of the morphology of nanostructured particles prepared by the spray drying of a nanoparticle sol. J Coll Interf Sci. 2003;265:296–303.
   PubMed Web of Science ®Google Scholar
• Sham JOH, Zhang Y, Finlay WH, et al. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm. 2004;269:457–467.
   PubMed Web of Science ®Google Scholar
• Ely L, Roa W, Finlay WH, et al. Effervescent dry powder for respiratory drug delivery. Eur J Pharm Biopharm. 2007;65:346–353.
   PubMed Web of Science ®Google Scholar
• Al-Qadi S, Grenha A, Carrión-Recio D, et al. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. J Controlled Release. 2012;157:383–390.
   PubMed Web of Science ®Google Scholar
• Jensen DK, Jensen LB, Koocheki S, et al. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J Controlled Release. 2012;157:141–148.
   PubMed Web of Science ®Google Scholar
• Abdelwahed W, Degobert G, Fessi H. A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization. Int J Pharm. 2006;309:178–188.
   PubMed Web of Science ®Google Scholar
• Abdelwahed W, Degobert G, Stainmesse S, et al. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58:1688–1713.
   PubMed Web of Science ®Google Scholar
• Cheow WS, Ng MLL, Kho K, et al. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants. Int J Pharm. 2011;404:289–300.
   PubMed Web of Science ®Google Scholar
• Azarmi S, Löbenberg R, Roa WH, et al. Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles. Drug Dev Ind Pharm. 2008;34:943–947.
   PubMed Web of Science ®Google Scholar
• El-Gendy N, Gorman EM, Munson EJ, et al. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci. 2009;98:2731–2746.
   PubMed Web of Science ®Google Scholar
• El-Gendy N, Desai V, Berkland C. Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols. J Pharm Innovat. 2010;5:79–87.
   Web of Science ®Google Scholar
• El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res. 2009;26:1752–1763.
   PubMed Web of Science ®Google Scholar
• El-Gendy N, Aillon KL, Berkland C. Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. Int J Pharm. 2010;391:305–312.
   PubMedGoogle Scholar
• Plumley C, Gorman EM, El-Gendy N, et al. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm. 2009;369:136–143.
   PubMed Web of Science ®Google Scholar
• Price DN, Stromberg LR, Kunda NK, et al. In vivo pulmonary delivery and magnetic targeting of dry powder nano-in-microparticles. Mol Pharm. 2017;14:4741–4750.
   PubMed Web of Science ®Google Scholar
• Zhang T, Chen Y, Ge Y, et al. Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers. Acta Pharm Sin B. 2018;8:440–448.
   PubMed Web of Science ®Google Scholar
• Chen R, Xu L, Fan Q, et al. Hierarchical pulmonary target nanoparticles via inhaled administration for anticancer drug delivery. Drug Deliv. 2017;24:1191–1203.
   PubMed Web of Science ®Google Scholar
• Card JW, Zeldin DC, Bonner JC, et al. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol. 2008;295:L400–11.
   PubMed Web of Science ®Google Scholar
• Menon JU, Kuriakose A, Iyer R, et al. Dual-drug containing core-shell nanoparticles for lung cancer therapy. Sci Rep. 2017;7:13249.
   PubMed Web of Science ®Google Scholar
• Yan Y, Liu L, Xiong H, et al. Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells. Proc Acad Sci USA. 2016;113:E5702–10.
   PubMed Web of Science ®Google Scholar